Hovinga, K. E., McCrea, H. J., Brennan, C., Huse, J. T., Zheng, J., Esquenazi, Y., . . . Tabar, V. (2019). EGFR amplification and classical subtype are associated with a poor response to bevacizumab in recurrent glioblastoma.
芝加哥风格引文Hovinga, Koos E., Heather J. McCrea, Cameron Brennan, Jason T. Huse, Junting Zheng, Yoshua Esquenazi, Katherine S. Panageas, 与 Viviane Tabar. EGFR Amplification and Classical Subtype Are Associated with a Poor Response to Bevacizumab in Recurrent Glioblastoma. 2019.
MLA引文Hovinga, Koos E., et al. EGFR Amplification and Classical Subtype Are Associated with a Poor Response to Bevacizumab in Recurrent Glioblastoma. 2019.
警告：这些引文格式不一定是100％准确.